

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Docket No.:

2883-US

Dirk M. Anderson

Serial No.:

09/887,855

Art Unit:

1653

Filing Date:

June 22, 2001

Examiner:

R. Mitra

For:

LECTIN SS3939 DNA AND POLYPEPTIDES

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to the duty of disclosure as set forth in 37 C.F.R. §1.56, §1.97 and §1.98, Applicant hereby discloses publications known to him which may be material to the patentability of this invention.

References B1 and C1 were cited in the International Search Report in the parent application (PCT/US99/30523).

For references B1, B2, and B3, Applicant is providing herewith a copy of only that portion of the reference that caused the reference to be listed: for B1 (WO99/14328 A2), the portion relating to PRO234 is provided; for B2 (WO 00/06698 A1), the portion relating to Gene 40 is provided; and for B3 (WO 01/42285 A2), the portion relating to XMAD-15 is provided. Applicant will provide the Examiner with the entire reference(s) upon request.

Kindly acknowledge receipt of this Statement and make the cited references of record in the subject application.

Since the submission of the documents listed on the Form PTO-1449 is made before the mailing of the first Office Action on the merits in connection with the above-captioned application, no fee under 37 C.F.R. 1.17(p) is believed to be required. However, should it be determined that a fee is necessary, Applicant authorizes the Commissioner to charge Applicant's deposit account no. 09-0089 in an amount necessary to permit consideration of this Information Disclosure Statement.

Respectfully submitted,

Suzanne A. Sprunger, Ph.D.

Reg. No. 41,323

Date: November 4, 2003

Immunex Corporation 51 University Street Seattle, WA 98101

Telephone: (206) 587-0430

## **CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

Date: Morenbu 4, 2003

Signed:

Elizabeth M. McCarthy

Form PTO-1449  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						ATTY. DOCKET NO. 2883-US	SERIAL NO. 09/887,855				
O INFORMATION DISCLOSURE CITATION  APPLICANT  Dirk M. ANDERSON											
NOV 0 7 2003 (E)se several sheets if necessary)						Filing Date: June 22, 2001		1653			
& TRADEN	3ARK			U.S. PA	TENT	DOCUMENTS					
EXAMINER		DOCUMENT NUMBER	DATE		NAME		CLAS	S SUBCLASS		FILING DATE F APPROPRIATE	
	<u>l</u>		FO	REIGN	PATE	NT DOCUMENTS	<u> </u>				
		DOCUMENT NUMBER		DATE		COUNTRY		S SUBCLASS	TRANSLATION YES NO		
	B1	WO 99/14328 A2	25 Mar 1999		WIPO						
	В2	WO 00/06698 A1	00/06698 A1 10 Feb 2000		WIP	0		•			
	B3 WO 01/42285 A2 1		14 June	14 June 2001		WIPO					
	B4 WO 01/42285 A3		14 June	14 June 2001		WIPO					
					<u></u>						
					ļ				-		
			<u> </u>		<u> </u>						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)											
	C1 Borowsky, M.L. <i>et al.</i> , "Layilin, a novel talin-binding transmembrane protein homologous with C-type lectins, is localized in membrane ruffles", <i>J Cell Biol</i> 143(2): 429-442, 19 October 1998										
	C2	Bono, P. et al., "Layilin, a novel integral membrane protein, is a hyaluronan receptor", Mol Biol Cell 12: 891-900, April 2001									
		<u> </u>									
					<del> </del>						
									<del></del>		
	<u> </u>	<u> </u>		<u> </u>							
EXAMINE	R										
*EVALAILU	ED. Imia:	al if aitation considered	whother =	r not sit-	tion is	in conformance with \$4	IDED 600-	Drow line the	uah aita	ion if	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											